Drug Pricing

Pharmaceutical giant Merck announced last week that it is taking the federal government to court over the Inflation Reduction Act’s drug pricing reforms. The lawsuit alleges that the law’s Medicare price negotiation program violates some of the most fundamental rights guaranteed by the U.S. Constitution. “This is not ‘negotiation,'” the company says ...

While local and national media outlets frequently report on food deserts, particularly in cities that lack sufficient grocery stores, there is one major shortage that goes largely unnoticed by the press: pharmacies. “Pharmacy deserts” pose a real threat, particularly for vulnerable populations. This is something I’ve seen firsthand. Last year, ...

Bill Smith of the Pioneer Institute in Massachusetts joins Wayne and Tim to discuss his important new book “Rationing Medicine”, which focuses on an obscure economic concept called QALYs – or quality adjusted life years. 

New research into COVID-19 has revealed some troubling findings. Even mild cases can lead to lasting heart complications. Comparing test data collected before and after a group of patients in their mid-30s contracted mild cases of COVID, researchers noticed an increase in arterial stiffness and cardiovascular inflammation. That means they may face “a widespread ...

Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.” Sen. Sanders is sure to call the pharmaceutical executives — ...

President Biden’s Inflation Reduction Act is just eight months old. It hasn’t yet slayed inflation. But it’s already gutting drug research and development. The law gives Medicare the power to impose price controls on certain prescription drugs for the first time. By September, federal officials will select the first 10 ...

The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...

Congress is beginning to push back on pharmaceutical benefit managers (PBMs). PRI’s Wayne Winegarden tells NTD News that a large problem lies in the lack of transparency in the drug pricing system. Reforming the PBM system could reduce costs for patients. Click to watch the interview on NTD News.